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To the Editor:
In a cohort of patients with differing severity of 
COVID-19 disease, including non-survivors, plasma 
proteomic analysis identified biomarkers of COVID-19 
disease progression [1]. The top pathways identified by 
Shu et  al. were those of platelet degranulation and the 
complement and coagulation cascades [1]. These iden-
tified pathways were complementary to another recent 
study comparing COVID-19 disease and control sub-
jects, where proteomic panels also identified biologi-
cal pathways involved in platelet degranulation and the 
coagulation cascade [2]. Whilst the comparison with 
absolute disease-free normality is relevant, an increasing 
proportion of the population have insulin resistant states 
with associated metabolic conditions; an example of 
such a metabolic condition is polycystic ovary syndrome 
(PCOS) where it has been shown that protein expression 
patterns may differ compared to those without PCOS 
[3]. Notably, in PCOS, platelet aggregation enhancement 
together with aberrant diminished plasma fibrinolytic 
activity potentially giving rise to enhanced thrombosis 
has been described [4, 5], with markers of coagulation 
being enhanced [6].
For a protein biomarker to be of value, there needs to 
be a clear discrimination between normal and disease 
condition levels. Therefore, platelet degranulation and 
the complement and coagulation cascade proteomic 
analysis was performed in women with and without 
PCOS to compare with these pathways described in 
COVID-19 disease [1].
243 subjects (146 PCOS and 97 control women) were 
recruited to the local PCOS biobank (ISRCTN70196169) 
[3] in the Department of Endocrinology, Hull and East 
Yorkshire Hospitals NHS Trust. The Rotterdam con-
sensus diagnostic criteria were used to diagnose PCOS. 
Proteins that were described for platelet degranulation 
(18 of 27 proteins) and the complement and coagulation 
cascades (16 of 19 proteins) [1] were measured using the 
Slow Off-rate Modified Aptamer (SOMA)-scan plasma 
protein measurement [7], shown in Table  1. Statistics 
were performed using Graphpad Prism 8.0.
As reported previously [3], whilst cohorts were age-
matched, the PCOS women differed in having increased 
systolic and diastolic blood pressure and waist circum-
ference (p < 0.05), together with increased insulin resist-
ance, increased androgens and C-reactive protein (CRP) 
(p < 0.001), indicative of metabolic dysfunction.
For the 46 protein biomarkers described by Shu et  al. 
[1], 34 were available for measurement in the Somalogic 
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Table 1 Proteins identified as being altered in COVID-19 disease categorized according to A, platelet degranulation; B, 
complement and coagulation cascades in non-COVID infected polycystic ovary syndrome (PCOS) and control women





















































































Vitronectin Vitronectin P04004 VTN 0.393
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Plasminogen Plasminogen P00747 PLG 0.674
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degranulation [fibrinogen-gamma chain (p = 0.00002), 
fibrinogen (p = 0.013), fibronectin (p = 0.0098) and 
kallistatin (p = 0.0006)], whilst 8 of 16 proteins for com-
plement and coagulation cascade (fibrinogen-gamma 
chain (p = 0.00002), fibrinogen (p = 0.013), comple-
ment factor 1 (p = 0.00000002), coagulation factor IX 
(p < 0.00001), complement factor H (p < 0.000000001), 
complement component C9 (p = 0.00002), plasma ser-
ine protease inhibitor (p = 0.038) and heparin cofactor 
2 (p = 0.00003) (Table  1). Moreover, those proteins that 
significantly differed between PCOS and controls share a 
close relationship to one another, as shown by the pro-
tein–protein interaction tool STRING (Search Tool for 
the Retrieval of Interacting Genes) pathways (Fig. 1).
The significant difference seen in PCOS compared to 
controls indicates the need for validation of such markers 
in the non-COVID-19 infected population before they 
can be considered as biomarkers for COVID-19 and its 
severity. Notably, based on the indication that COVID-19 
severity can be related to these markers, their detection 
in a PCOS COVID-19 positive patient may give a false 
impression of severity, potentially leading to the intro-
duction of inappropriate therapy; conversely, the detec-
tion of these specific markers in women with PCOS 
may actually indicate that more proactive intervention 
is required, as these women may have a propensity for 
increased COVID-19 disease severity [8].
Limitations of the study include that the Somalogic 
panel did not include all of the proteins that were pre-
viously reported, and the proteomic analysis differed so 
may not be directly comparable to the Shu et al. study [1] 
or others [2]. Nonetheless, the majority of proteins were 
common to both proteomic platforms.
In conclusion, 12 of 34 protein biomarkers contained 
within the platelet degranulation and complement and 
coagulation cascades and purported to indicate disease 
progression in patients infected with COVID-19, differed 
between non-COVID-19 infected PCOS and control 
Table 1 (continued)
Students’ t-test was used to determine differences between protein levels. Proteins that differed significantly (p < 0.05) are shown in red font. Proteins that are 
common to both the platelet degranulation and the complement/coagulation cascades are shaded in orange
Fig. 1 The protein–protein interaction tool STRING 11.0 (Search Tool for the Retrieval of Interacting Genes) was used to visualize the significantly 
different proteins in PCOS compared to controls, and for all of the proteomic proteins in COVID-19 disease severity described by others [1] (https 
://strin g-db.org/). Interactions between proteins are evidence-based and collated from databases, experiments, neighborhood, gene fusion, 
co-occurrence, text mining, co-expression, and homology. Here, we determined the relationships between the platelet degranulation (a) and 
complement and coagulation cascade proteins (b) presented in the study by Shu et al. [1] that were significantly different between non-COVID 
infected PCOS and control women. a Platelet degranulation proteins that differed significantly between PCOS and control women, indicating 
their relationship to one another. b Complement and coagulation cascade proteins that differed significantly between PCOS and control women, 
indicating their relationship to one another. c Combined platelet degranulation and complement and coagulation cascade proteins that differed 
significantly in PCOS, indicating their relationships to one another
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women. This indicates that validation of such proposed 
COVID-19 specific biomarkers is a necessity, although it 
is unclear if this places PCOS women at increased risk of 
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